Skip to content
Screener

Accounts Payable at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$47.7M+109%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$100M+4.2%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$43.67M+38.3%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$23.39M-18.9%
CalAmp logo
CalAmpCAMP
$863K-38.3%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$28.6M+63.8%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemMarch 31, 2026December 31, 2025
Total assets$443,277$418,434
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$6,839$4,939
Accrued and other current liabilities23,90141,035
Deferred revenue - current portion10,06611,901
Total current liabilities$40,806$57,875
Deferred revenue - net of current portion6,6036,961

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s accounts payable?
Stoke Therapeutics, Inc. (STOK) reported accounts payable of $6.84M in Q1 2026.
How has Stoke Therapeutics, Inc.'s accounts payable changed year-over-year?
Stoke Therapeutics, Inc.'s accounts payable increased by 212.9% year-over-year, from $2.19M to $6.84M.
What is the long-term trend for Stoke Therapeutics, Inc.'s accounts payable?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s accounts payable has grown at a 27.0% compound annual growth rate (CAGR), from $1.5M to $4.94M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Ask your AI about Stoke Therapeutics, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude